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Introduction {#embr201642412-sec-0001}
============

Innate lymphoid cells (ILCs) are a family of immune cells that play a central role in a variety of physiological processes including immune regulation, modulation of interactions with the microbiota, tissue repair and lymphoid tissue development [1](#embr201642412-bib-0001){ref-type="ref"}. ILCs can be classified in three families based on their cytokine secretion and the transcription factors required for their development: ILC1s (T‐bet^+^) produce IFN‐γ; ILC2s (GATA‐3^+^) secrete IL‐5 and IL‐13; and ILC3s (RORγt^+^) produce IL‐17 and IL‐22 [2](#embr201642412-bib-0002){ref-type="ref"}. Accordingly, ILCs can modulate immune cell function through cytokine secretion but also through direct cell--cell interactions. Recent studies have identified an unexpected function for ILCs as antigen presenting cells (APCs) in the regulation of CD4^+^ T‐cell immunity. As such, both ILC2s and ILC3s can internalize and present antigens on MHC‐II to control cognate T‐cell activation [3](#embr201642412-bib-0003){ref-type="ref"}, [4](#embr201642412-bib-0004){ref-type="ref"}, [5](#embr201642412-bib-0005){ref-type="ref"}, [6](#embr201642412-bib-0006){ref-type="ref"}, [7](#embr201642412-bib-0007){ref-type="ref"}, T helper 17 cell differentiation [8](#embr201642412-bib-0008){ref-type="ref"} and the intestinal selection of commensal bacteria‐specific CD4^+^ T cells [9](#embr201642412-bib-0009){ref-type="ref"}. Concurrently, ILC--T‐cell crosstalk promotes ILC activation and cytokine production [4](#embr201642412-bib-0004){ref-type="ref"}, [5](#embr201642412-bib-0005){ref-type="ref"}, evidencing a bidirectional dialogue between the innate and adaptive immune systems.

Similar to the MHC‐dependent recognition of protein antigens by conventional T cells, a broad range of lipids associated with CD1d molecules specifically activate a population of unconventional T cells called invariant natural killer T (iNKT) cells [10](#embr201642412-bib-0010){ref-type="ref"}, [11](#embr201642412-bib-0011){ref-type="ref"}. Consequently, iNKT cells recognize through their T‐cell receptors (TCR) CD1d‐restricted self‐lipids as well as lipids from pathogenic bacteria, commensals or fungi, contributing to the establishment of immune homeostasis and to anti‐microbial, anti‐tumour and autoimmune responses [10](#embr201642412-bib-0010){ref-type="ref"}, [11](#embr201642412-bib-0011){ref-type="ref"}. Evidence suggests that the context of lipid presentation provided by diverse CD1d^+^ APCs can shape the outcome of immune responses, by tuning the extent of iNKT cell activation, their proliferation and their pattern of cytokine secretion [12](#embr201642412-bib-0012){ref-type="ref"}, [13](#embr201642412-bib-0013){ref-type="ref"}, [14](#embr201642412-bib-0014){ref-type="ref"}. Conversely, iNKT cell--APC interactions can modulate APC activation and function [14](#embr201642412-bib-0014){ref-type="ref"}, [15](#embr201642412-bib-0015){ref-type="ref"}, [16](#embr201642412-bib-0016){ref-type="ref"}, [17](#embr201642412-bib-0017){ref-type="ref"}, [18](#embr201642412-bib-0018){ref-type="ref"}, [19](#embr201642412-bib-0019){ref-type="ref"}, [20](#embr201642412-bib-0020){ref-type="ref"}. For instance, iNKT cell activation in response to glycolipid recognition results in CD40 ligand‐dependent maturation of dendritic cells (DC), favouring cross‐presentation and enhancing CD4, CD8 and B‐cell responses [18](#embr201642412-bib-0018){ref-type="ref"}, [19](#embr201642412-bib-0019){ref-type="ref"}, [20](#embr201642412-bib-0020){ref-type="ref"}. Remarkably, engagement of CD1d is sufficient to induce activation and secretion of cytokines by both professional (DCs, monocytes) and unconventional (intestinal epithelial cells; IECs) APCs resulting in modulation of immunity in homeostasis and inflammation [14](#embr201642412-bib-0014){ref-type="ref"}, [21](#embr201642412-bib-0021){ref-type="ref"}, [22](#embr201642412-bib-0022){ref-type="ref"}, [23](#embr201642412-bib-0023){ref-type="ref"}. For example, ligation of CD1d in IEC leads to secretion of IL‐10 rendering protective effects in murine models of inflammatory bowel disease (IBD) [14](#embr201642412-bib-0014){ref-type="ref"}, [21](#embr201642412-bib-0021){ref-type="ref"}.

ILCs are emerging as central regulators of immunity, yet their possible contribution to lipid‐dependent immune responses has never been explored. Here we show that ILCs from murine tissues express the lipid‐presenting molecule CD1d with the highest levels of expression corresponding to ILC3s. Using fluorescent lipids and presentation assays, we demonstrate that primary ILC3s are able to internalize and load lipids on CD1d for recognition by the TCR of iNKT cells. Conversely, engagement of CD1d on ILC3s *in vitro* and administration of antigenic lipids *in vivo* induce ILC3 activation and secretion of IL‐22. Thus, our data reveal a previously unknown function for ILC3s on CD1d‐dependent immunity.

Results and Discussion {#embr201642412-sec-0002}
======================

ILCs express CD1d {#embr201642412-sec-0003}
-----------------

To investigate the expression of the lipid‐presenting molecule CD1d by ILCs, we first identified them as lineage (Lin)^−^CD45^+^CD127^+^ cells and then used the expression of T‐bet, GATA‐3 and RORγt to discriminate the ILC1, ILC2 and ILC3 populations, respectively (Figs [1](#embr201642412-fig-0001){ref-type="fig"} and [EV1](#embr201642412-fig-0001ev){ref-type="fig"}). We detected CD1d expression in the putative ILC population (Lin^−^CD45^+^CD127^+^) within the mesenteric lymph nodes (mLN), spleen, Peyer\'s patches (PP), small intestinal lamina propria (SI‐LP), colonic LP and lung from WT mice in comparison with ILCs from CD1d‐deficient mice (Fig [EV1](#embr201642412-fig-0001ev){ref-type="fig"}A). The level of CD1d expression in ILCs was generally comparable to DCs and at least 10 times higher than CD45^−^ cells (Fig [1](#embr201642412-fig-0001){ref-type="fig"}A). In all analysed tissues, RORγt^+^ ILCs exhibited the highest levels of CD1d amongst the ILC populations, while T‐bet^+^ ILCs showed the lowest levels (Fig [1](#embr201642412-fig-0001){ref-type="fig"}B). Previous studies have shown that intestinal RORγt^+^ ILCs display a gradient of T‐bet that controls their fate and function and ILC3s can up‐regulate T‐bet and down‐regulate RORγt acquiring functional and phenotypical features of ILC1s [24](#embr201642412-bib-0024){ref-type="ref"}, [25](#embr201642412-bib-0025){ref-type="ref"}. Accordingly, we detected that intestinal RORγt^+^ ILCs show variable expression of T‐bet, which correlated inversely with the levels of CD1d (Figs [1](#embr201642412-fig-0001){ref-type="fig"}B and [EV1](#embr201642412-fig-0001ev){ref-type="fig"}B and C). Finally, analysis of gene expression by quantitative PCR showed CD1d mRNA expression on ILC3s sorted from the tissues of WT mice in comparison with ILC3s isolated from CD1d‐deficient mice (Fig [1](#embr201642412-fig-0001){ref-type="fig"}C). Thus, ILCs express CD1d with the higher levels of expression corresponding to RORγt^+^ ILC3s.

![CD1d expression on ILCs\
Flow cytometry for CD1d expression (top) and CD1d mean fluorescence intensity (MFI; bottom) on CD45^−^ cells, ILCs (Lin^−^CD45^+^CD127^+^), DCs (CD11c^+^) and B cells (B220^+^) of the depicted tissues from WT mice (*n* = 4).Flow cytometry profiles showing gating strategy (dot plots), CD1d expression (histograms) and CD1d MFI (bars) in T‐bet^+^ (empty profile), GATA‐3^+^ (dark grey), RORγt^+^ (light grey) and T‐bet^+^RORγt^+^ (dotted line) ILCs in mLN, spleen, PP and SI‐LP (*n* = 5). Numbers indicate percentage of cells in the depicted gates.Quantitative RT--PCR analysis of mRNA encoding CD1d in freshly isolated ILC3s (from mLN of CD1d‐deficient mice and mLN and spleen of WT mice), B cells and DCs (*n* = 3). Results are normalized to those of *GAPDH*; RE, relative expression. \*\**P* \< 0.01 (two‐tailed unpaired *t*‐test).Flow cytometry profiles showing NKp46 and RORγt expression in Lin^−^CD45^+^ cells; CD1d and CCR6 expression in NCR^−^ ILC3s; and CD1d and CD4 expression in NCR^−^CCR6^+^ ILC3s from mLN and SI‐LP (*n* = 4). Numbers indicate percentage of cells in the depicted gates.CD1d expression (histograms) and CD1d MFI in NCR^+^ (empty profile), NCR^−^CCR6^−^ (dark grey) and NCR^−^CCR6^+^ (light grey) ILC3s from mLN and SI‐LP (*n* = 4).Data information: Graphs represent mean ± SEM. Data are from three (A, C--E) or five (B) independent experiments.](EMBR-18-39-g002){#embr201642412-fig-0001}

![CD1d expression on ILCs\
Flow cytometry profiles showing gating strategy and CD1d expression (histogram) in Lin^−^CD45^+^CD127^+^ cells in the depicted tissues from WT (grey filled, *n* = 4) and CD1d‐deficient (empty profile, *n* = 4) mice.Flow cytometry profiles showing gating strategy and CD1d expression (histograms) in T‐bet^+^ (empty profile), T‐bet^+^RORγt^+^ (dotted line), GATA‐3^+^ (dark grey) and RORγt^+^ (light grey) ILCs in colonic lamina propria (*n* = 3). Numbers indicate percentage of cells in the depicted gates.Flow cytometry profiles showing expression of CD1d and T‐bet in Lin^−^CD45^+^CD127^+^RORγt^+^ cells from mLN, spleen and SI‐LP as indicated (*n* = 4); numbers indicate percentage of cells. Right panel, percentage of CD1d^hi^ ILC3s in the depicted tissues. \*\*\**P* \< 0.001 two‐tailed unpaired *t*‐test.Relative expression (*RE*) of lymphotoxin‐alpha (*LTA*) mRNA (qPCR, normalized to *GAPDH*) in sort‐purified CD1d^hi^CCR6^hi^ (light grey) and CD1d^low^CCR6^low^ (dark grey) ILC3s isolated from mLN or spleen; \*\**P* \< 0.01, two‐tailed unpaired *t*‐test.Data information: Graphs represent mean ± SEM. Data are from three independent experiments.](EMBR-18-39-g003){#embr201642412-fig-0001ev}

The ILC3 population is heterogeneous and comprises several subfamilies with distinctive phenotypic and functional characteristics including: (i) lymphoid tissue inducer (LTi) cells (CCR6^+^NKp46^−^) which are crucial for the formation of secondary lymphoid organs and produce lymphotoxin, IL‐17A and IL‐22. LTi cells include CD4^−^ and CD4^+^ cells; (ii) natural cytotoxicity triggering receptor (NCR)^−^ ILC3s (NKp46^−^) secrete IL‐17A and/or IL‐22 and have been associated with inflammatory conditions. NCR^−^ ILC3s can give rise to NCR^+^ ILC3s in a process dependent on T‐bet; and (iii) NCR^+^ ILC3s (NKp46^+^) that secrete IL‐22 but not IL‐17A and participate in the regulation of intestinal homeostasis [2](#embr201642412-bib-0002){ref-type="ref"}, [26](#embr201642412-bib-0026){ref-type="ref"}. To interrogate the levels of CD1d expression in the different ILC3 subpopulations, we performed additional phenotypical analyses of ILC3s from different tissues (Figs [1](#embr201642412-fig-0001){ref-type="fig"}D and E, and [EV1](#embr201642412-fig-0001ev){ref-type="fig"}, [EV2](#embr201642412-fig-0002ev){ref-type="fig"} and [EV3](#embr201642412-fig-0003ev){ref-type="fig"}). As previously described, we found that the majority of RORγt^+^ ILC3s in the mLN were NCR^−^CCR6^+^ cells [7](#embr201642412-bib-0007){ref-type="ref"} which expressed high levels of CD1d (Fig [1](#embr201642412-fig-0001){ref-type="fig"}D and E) and lymphotoxin‐alpha (*LTA*) mRNA but lacked T‐bet (Fig [EV1](#embr201642412-fig-0001ev){ref-type="fig"}C and D). Within the SI‐LP, we found low CD1d expression in NCR^+^ and NCR^−^CCR6^−^ ILC3s in comparison with NCR^−^CCR6^+^ cells (Fig [1](#embr201642412-fig-0001){ref-type="fig"}D and E). Finally, CD1d^hi^ ILC3 showed high expression of CD117 (c‐kit), lacked PLZF, and showed heterogeneous expression of MHC‐II, CD4, and CD90, which were also differentially expressed on RORγt^+^ ILCs from various tissues (Figs [EV2](#embr201642412-fig-0002ev){ref-type="fig"} and [EV3](#embr201642412-fig-0003ev){ref-type="fig"}). Thus, ILCs express CD1d with the higher levels of expression corresponding to NCR^−^CCR6^+^ ILC3s.

![Phenotype of CD1d^+^ ILCs in mLN\
Flow cytometry profiles showing expression of the depicted markers in Lin^−^CD45^+^CD127^+^ cells from mLN. Numbers indicate percentage of cells in the depicted gates. Data represent 2--4 independent experiments.](EMBR-18-39-g005){#embr201642412-fig-0002ev}

![Phenotype of RORγt^+^ ILCs\
Flow cytometry profiles showing expression of the depicted markers in RORγt^+^Lin^−^CD45^+^CD127^+^ ILC3s from mLN, spleen and SI‐LP as indicated. Numbers indicate percentage of cells in the depicted gates. Data represent 2--5 independent experiments.](EMBR-18-39-g007){#embr201642412-fig-0003ev}

RORγt^+^CCR6^+^ ILC3s are a developmentally independent subset originally described to promote lymphoid organogenesis and which are major producers of IL‐22 in homeostatic conditions and during infection [24](#embr201642412-bib-0024){ref-type="ref"}, [27](#embr201642412-bib-0027){ref-type="ref"}. In the intestine, RORγt^+^CCR6^+^ ILC3s expressing MHC‐II control intestinal homeostasis through cognate interactions with CD4^+^ T cells [3](#embr201642412-bib-0003){ref-type="ref"}, [8](#embr201642412-bib-0008){ref-type="ref"}, [9](#embr201642412-bib-0009){ref-type="ref"}. In the adult spleen, RORγt^+^CCR6^+^ ILC3s promote CD4^+^ T‐cell responses and enhance antibody production by marginal zone B cells [4](#embr201642412-bib-0004){ref-type="ref"}, [28](#embr201642412-bib-0028){ref-type="ref"}. The fact that CD1d expression is particularly high in RORγt^+^CCR6^+^ ILC3s points towards a possible contribution of ILC3s to CD1d‐mediated immunity either in the establishment of mucosal homeostasis or during inflammatory or infectious immune responses.

ILC3s internalize lipids and mediate CD1d‐dependent lipid presentation {#embr201642412-sec-0004}
----------------------------------------------------------------------

Next, we investigated the capacity of ILCs to internalize and load lipids on CD1d for presentation to the TCR of iNKT cells (Fig [2](#embr201642412-fig-0002){ref-type="fig"}). Because ILC3s express the highest levels of surface CD1d (Fig [1](#embr201642412-fig-0001){ref-type="fig"}), we focussed on this population for our functional assays.

![ILC3s internalize and present lipid antigens to iNKT cells\
ACells were cultured in the presence or absence of BODIPY‐αGalCer at 4 or 37°C as indicated. Flow cytometry profiles and percentages of BODIPY‐αGalCer^+^ DC or ILC3 from the indicated tissues incubated at 4°C (white bars) or 37°C (grey bars) are shown (*n* = 3).BWT mice were intravenously injected with BODIPY‐αGalCer or PBS (control); lipid uptake was analysed by flow cytometry in the depicted populations from the spleen 16 h after lipid injection (*n* = 3). Numbers indicate percentage of cells in the depicted gates.CIL‐2 secretion by DN32.D3 cells co‐cultured with ILC3 sort‐purified from mLN or spleen as indicated, pulsed (+) or not (−) with αGalCer and with or without αCD1d‐blocking antibody.D--FSort‐purified ILC3s were preincubated with αGalCer (ILC3(αGal)) or PBS (ILC3(cont)) and adoptively transferred into WT recipients. (D) Experimental protocol; (E) fold change in mRNA expression for the indicated cytokines in iNKT cells sort‐purified from spleen, mLN or SI‐LP of mice injected with αGalCer‐loaded ILC3s. Gene expression was measured by qPCR, normalized to *GAPDH* and presented as expression relative to iNKT cells sort‐purified from mice injected with control ILC3s (*n* = 3--5). (F) Intracellular cytokine staining (left) and percentage of cytokine^+^ cells (right) in splenic iNKT cells from ILC3‐recipient mice (*n* = 3). Numbers indicate percentage of cells in the depicted gates. \*\**P* \< 0.01, two‐tailed unpaired *t*‐test.Data information: Graphs represent mean ± SEM. Data are from more than two independent experiments.](EMBR-18-39-g004){#embr201642412-fig-0002}

First, we tested the ability of ILC3s to acquire lipids by incubating sort‐purified ILC3s with a fluorescent synthetic form of the CD1d‐binding iNKT cell‐activating model lipid αGalCer (BODIPY‐αGalCer; Fig [2](#embr201642412-fig-0002){ref-type="fig"}A). After incubation with fluorescent lipids *in vitro*, ILC3s exhibited an increase in fluorescence intensity (comparable to control DCs) indicative of an ability to acquire lipid antigens, while lipid uptake was severely impaired when incubation was performed at 4°C (Fig [2](#embr201642412-fig-0002){ref-type="fig"}A). Since ILC3s are located in the marginal zone of the spleen [28](#embr201642412-bib-0028){ref-type="ref"} where lipids can be efficiently retained when arriving in the circulation [29](#embr201642412-bib-0029){ref-type="ref"}, we tested whether splenic ILC3s have the capacity to acquire lipid antigens *in vivo* (Fig [2](#embr201642412-fig-0002){ref-type="fig"}B). To investigate this, we injected fluorescent lipids intravenously in WT mice and analysed lipid acquisition by ILC3s and DCs by flow cytometry. We observed that 16 h after lipid injection, a proportion of splenic ILC3s and DCs showed an increase in fluorescence intensity revealing their ability to acquire lipids *in vivo* (Fig [2](#embr201642412-fig-0002){ref-type="fig"}B). Multiple mechanisms may collaborate to mediate lipid internalization by ILC3s and such processes often are determined by the nature of the antigen (i.e. lipoproteins, particulate material, pathogens). A variety of receptors expressed by many cell types (such as low‐density lipoprotein receptor (LDL‐R) or scavenger receptors) have been proposed to mediate lipid antigen uptake and direct such lipids towards the CD1d presentation pathway [30](#embr201642412-bib-0030){ref-type="ref"}, [31](#embr201642412-bib-0031){ref-type="ref"}, [32](#embr201642412-bib-0032){ref-type="ref"}. For instance, exogenous lipids can be incorporated into VLDL particles, which can then be internalized through LDL receptor‐mediated uptake [31](#embr201642412-bib-0031){ref-type="ref"}, [32](#embr201642412-bib-0032){ref-type="ref"}. Moreover, the uptake of pathogens or particulate material by phagocytosis delivers exogenous lipid antigens into the endocytic system, where CD1d molecules can bind them [30](#embr201642412-bib-0030){ref-type="ref"}. Importantly ILC3s can internalize proteins and latex beads [3](#embr201642412-bib-0003){ref-type="ref"}, [4](#embr201642412-bib-0004){ref-type="ref"} as well as lipids, which suggests that they may be able to use a variety of mechanisms to sample their environment.

Next, we examined the capacity of ILC3s to load lipids on CD1d and to present them to iNKT cells (Fig [2](#embr201642412-fig-0002){ref-type="fig"}C--F). Sort‐purified ILC3s (from mLN or spleen) were pre‐incubated with lipids for 2 h and co‐cultured with iNKT hybridoma cells (DN32.D3). As shown in Fig [2](#embr201642412-fig-0002){ref-type="fig"}C, αGalCer was efficiently presented by ILC3s as defined by IL‐2 production by iNKT cells. Importantly, lipid presentation was dependent on CD1d as IL‐2 secretion was strongly reduced in the presence of a CD1d‐blocking antibody (Fig [2](#embr201642412-fig-0002){ref-type="fig"}C). To further test whether ILC3s could mediate CD1d‐dependent lipid presentation *in vivo*, we loaded sort‐purified ILC3s with lipids (or PBS as control), transferred them into WT recipients and measured activation of iNKT cells sort‐purified from spleen, mLN and SI‐LP of the recipient mice (Fig [2](#embr201642412-fig-0002){ref-type="fig"}D--F). Lipid‐loaded ILC3s induced activation of iNKT cells as evidenced by an increase in the expression of cytokines detected by qPCR (Fig [2](#embr201642412-fig-0002){ref-type="fig"}E). Consistent with these data, intracellular stainings showed increased IFN‐γ and IL‐4 production by splenic iNKT cells from mice receiving lipid‐loaded ILC3s (Fig [2](#embr201642412-fig-0002){ref-type="fig"}F).

Altogether our data demonstrate that ILC3s can internalize lipids, load them on CD1d and present them to iNKT cells both *in vitro* and *in vivo*. The capacity of ILC3s to mediate CD1d‐dependent lipid presentation points towards an ILC3‐iNKT cell dialogue that could modulate the initiation and/or progression of the immune response. It is worth noting that in the adult spleen, both ILC3 and iNKT cells are located in the splenic marginal zone [28](#embr201642412-bib-0028){ref-type="ref"}, [29](#embr201642412-bib-0029){ref-type="ref"}, which may favour their crosstalk and the early initiation of immune responses. Within the intestine, iNKT cells function and features are modulated by CD1d‐dependent recognition of commensal‐derived lipids [33](#embr201642412-bib-0033){ref-type="ref"}, [34](#embr201642412-bib-0034){ref-type="ref"}, [35](#embr201642412-bib-0035){ref-type="ref"}. Since ILC3s modulate CD4^+^ T‐cell responses to commensal bacteria [3](#embr201642412-bib-0003){ref-type="ref"}, [8](#embr201642412-bib-0008){ref-type="ref"}, [9](#embr201642412-bib-0009){ref-type="ref"}, it is conceivable that they could internalize and present commensal‐derived lipids to iNKT cells consequently regulating intestinal iNKT cell immunity. Further studies will allow defining the functional consequences of ILC3‐mediated lipid presentation *in vivo* both in homeostasis and during inflammatory and infectious responses.

Engagement of CD1d on ILC3s drives IL‐22 secretion {#embr201642412-sec-0005}
--------------------------------------------------

Next, we investigated the consequences of CD1d expression for ILCs\' homeostasis and function. First, we tested whether CD1d expression and/or NKT cells could influence the ILC populations in steady state. T cells are known to regulate ILC numbers and function [7](#embr201642412-bib-0007){ref-type="ref"}, [36](#embr201642412-bib-0036){ref-type="ref"} and ILC populations are altered in RAG^−/−^, TCRα^−/−^ and ZAP70^−/−^ mice that show a marked increase in the percentage of ILC2s in their mLN at the expense of ILC3s [7](#embr201642412-bib-0007){ref-type="ref"}. Likewise, NKT cells regulate immune cells in steady state including memory CD8^+^ T cells and IgE production by B cells [37](#embr201642412-bib-0037){ref-type="ref"}. To determine whether NKT cells/CD1d regulate ILC development, we examined ILCs in CD1d‐deficient mice (which also lack NKT cells; Figs [3](#embr201642412-fig-0003){ref-type="fig"}A and B, and [EV4](#embr201642412-fig-0004ev){ref-type="fig"}). We found that ILC populations were comparable in CD1d^−/−^ mice and WT littermates, suggesting that neither CD1d nor NKT cells play a major role in the regulation of ILC development and/or homeostasis (Figs [3](#embr201642412-fig-0003){ref-type="fig"}A and B, and [EV4](#embr201642412-fig-0004ev){ref-type="fig"}).

![Engagement of CD1d on ILC3s induces IL‐22 production\
A, BFlow cytometry plots showing gating strategy (A) and percentage of ILC populations (from Lin^−^CD45^+^CD127^+^ cells, B) in mLN from WT (*n* = 4) and CD1d‐deficient (*n* = 3) mice.CFold change in mRNA expression for the indicated cytokines in ILC3s after antibody‐mediated CD1d cross‐link (*n* = 3). Gene expression was measured by qPCR and normalized to *GAPDH* and to the mRNA expression levels in control ILC3s. \**P* \< 0.05 two‐tailed unpaired *t*‐test.DFold change in *IL22* mRNA expression in ILC3s after antibody‐mediated CD1d cross‐link and/or IL‐23 stimulation (*n* = 4). Gene expression was measured by qPCR and normalized to *GAPDH* and to the mRNA expression levels in control ILC3s. \*\**P* \< 0.01 two‐tailed unpaired *t*‐test.EIL‐22 detection by ELISA in the supernatant of ILC3s cultured in the presence of αCD1d and/or IL‐23 (*n* = 3). \**P* \< 0.05 two‐tailed unpaired *t*‐test.F, GIntracellular cytokine staining (F) and percentage of IL‐22^+^ ILC3s (G) after stimulation with αCD1d, IL‐23 and/or IL‐1β. \**P* \< 0.05, \*\**P* \< 0.01 two‐tailed unpaired *t*‐test (*n* = 4--8)HWT mice were i.v. injected with αGalCer or PBS (control) and activation of splenic ILC3s was assessed by flow cytometry as CD69 up‐regulation at 6 or 16 h after injection. Grey filled profile, ILC3 from αGalCer‐injected mice; empty profile, ILC3 from PBS‐injected mice; dotted line, CD45^−^ cells. Right graph, percentage of CD69^+^ ILC3s 6 h after injection of αGalCer (grey) or PBS (white) (*n* = 3). \**P* \< 0.05 two‐tailed unpaired *t*‐test.I, JFold change in mRNA expression for the indicated cytokines in ILC3s sort‐purified from spleen (I) or SI‐LP (J) 6 h after intravenous (I) or oral (J) αGalCer administration. Gene expression was measured by qPCR and normalized to *GAPDH* and to the expression levels in ILC3s sort‐purified from PBS‐injected mice (*n* = 3). \**P* \< 0.05, \*\**P* \< 0.01 two‐tailed unpaired *t*‐test.Data information: Graphs represent mean ± SEM.](EMBR-18-39-g006){#embr201642412-fig-0003}

![ILCs in WT and CD1d‐deficient mice\
Flow cytometry profiles showing ILC populations from SI‐LP and spleen in WT and CD1d‐deficient mice as indicated. Data represent four independent experiments.](EMBR-18-39-g008){#embr201642412-fig-0004ev}

We then explored whether CD1d expression can shape the function of ILC3s. Previous studies have shown that engagement of CD1d results in secretion of cytokines by both professional and unconventional APCs including IL‐10 secreted by IEC and IL‐12 by DCs and monocytes [21](#embr201642412-bib-0021){ref-type="ref"}, [22](#embr201642412-bib-0022){ref-type="ref"}. Consequently, engagement of epithelial CD1d renders protective effects in mouse models of IBD, while CD1d‐mediated production of IL‐12 by APCs leads to protection against viral infection [14](#embr201642412-bib-0014){ref-type="ref"}, [23](#embr201642412-bib-0023){ref-type="ref"}. To study whether CD1d could regulate ILC3 function, we performed antibody‐mediated cross‐linking of CD1d on ILC3s and measured changes in the expression of *IL22*,*IL17A, LTA* and *LTB* (cytokines typically produced by ILC3s) as well as *TNFSF13B* (BAFF), *TNFSF1*3 (APRIL) and *CD40LG* (CD40L; factors by which ILC3s modulate B‐cell function [28](#embr201642412-bib-0028){ref-type="ref"}; Figs [3](#embr201642412-fig-0003){ref-type="fig"}C and [EV5](#embr201642412-fig-0005ev){ref-type="fig"}). Strikingly, CD1d ligation on ILC3s resulted in a prominent increase in the expression of *IL22* mRNA (Fig [3](#embr201642412-fig-0003){ref-type="fig"}C and D), suggesting that CD1d engagement is sufficient to induce cytokine production by ILC3s. Consistent with these data, we detected increased IL‐22 production by ILC3s after CD1d cross‐link by ELISA and intracellular staining (Fig [3](#embr201642412-fig-0003){ref-type="fig"}E--G). ILC3s are known to produce IL‐22 in response to a variety of environmental cues including cytokines (i.e. IL‐23) or Toll‐like receptor (TLR) ligands; and combinations of such stimuli may skew ILC3 activation and differentiation [4](#embr201642412-bib-0004){ref-type="ref"}, [38](#embr201642412-bib-0038){ref-type="ref"}. Interestingly, we observed that CD1d engagement on ILC3s acts synergistically with IL‐23 to induce increased IL‐22 production (Fig [3](#embr201642412-fig-0003){ref-type="fig"}D--G). It seems likely that in the context of an immune response CD1d signals could function together with other factors (i.e. IL‐23, IL‐1β,TLR ligands) to modulate ILC3 activation and subsequently control the local cytokine milieu to maintain homeostasis and/or regulate inflammatory or infectious responses. Although the molecular mechanisms by which CD1d engagement modulates IL‐22 production will require further investigation, it has been recently shown that CD1d engagement in IEC leads to STAT3 phosphorylation and STAT3‐dependent cytokine secretion [14](#embr201642412-bib-0014){ref-type="ref"}. Interestingly, activated STAT3 can directly bind the *IL22* locus on ILC3s controlling IL‐22 production [39](#embr201642412-bib-0039){ref-type="ref"}, which may suggest STAT proteins as a possible mechanistic link between CD1d signalling and IL‐22 secretion.

![Effect of CD1d cross‐link on ILC3s\
Fold change in mRNA expression for the indicated cytokines in ILC3s after antibody‐mediated CD1d cross‐link (*n* = 4). Gene expression was measured by qPCR and normalized to *GAPDH* and to the mRNA expression levels in control ILC3s. Graphs represent mean ± SEM.Flow cytometry profiles showing MHC‐II expression on ILC3s in after cross‐link with αCD1d antibody (grey) or control (white).Data information: Data are from four independent experiments.](EMBR-18-39-g009){#embr201642412-fig-0005ev}

Finally, we tested whether ILC3s could participate in CD1d‐mediated immune responses *in vivo*. To explore this, we administered αGalCer to WT mice, either intravenously or orally, and analysed changes on the features of ILC3s in response to lipid administration in the spleen or SI‐LP, respectively (Fig [3](#embr201642412-fig-0003){ref-type="fig"}H--J). We detected activation of splenic ILC3, evidenced by CD69 up‐regulation, as early as 6 h after intravenous lipid injection (Fig [3](#embr201642412-fig-0003){ref-type="fig"}H). Moreover, and in agreement with our *in vitro* data, ILC3s sorted from αGalCer‐injected mice showed a marked increase in the expression of *IL22* in comparison with ILC3s from control mice (Fig [3](#embr201642412-fig-0003){ref-type="fig"}I). Also, oral administration of αGalCer resulted in increased *IL22* production by intestinal ILC3s (Fig [3](#embr201642412-fig-0003){ref-type="fig"}J), in line with a functional role for ILC3s in the regulation of lipid‐mediated immunity within the intestine. Although IL‐22 generally supports epithelial barrier function and tissue repair, it can also promote proinflammatory responses and its levels are often high in chronic inflammatory conditions [40](#embr201642412-bib-0040){ref-type="ref"}. Moreover, IL‐22 contributes to the control of bacterial and fungal infection, and to protective barrier functions during viral infections [41](#embr201642412-bib-0041){ref-type="ref"}. Since lipid‐dependent activation of immune cells modulates the outcome of a variety of infectious and inflammatory diseases [10](#embr201642412-bib-0010){ref-type="ref"}, [11](#embr201642412-bib-0011){ref-type="ref"}, [14](#embr201642412-bib-0014){ref-type="ref"}, [16](#embr201642412-bib-0016){ref-type="ref"}, it is likely that ILC3s contribute to lipid‐mediated immunity in those contexts through secretion of IL‐22, consequently shaping the initiation or development of the immune response.

All together, our data identify a novel pathway for immune regulation mediated by CD1d expression on ILC3s. We show that ILC3s can internalize and present lipids on CD1d and that CD1d‐dependent activation of ILC3s induces secretion of IL‐22. This pathway could have implications for a variety of immune responses where CD1d‐dependent immunity plays a central role [10](#embr201642412-bib-0010){ref-type="ref"}, [11](#embr201642412-bib-0011){ref-type="ref"}. For instance, CD1d contributes to the functional regulation of immune cells in a variety of autoimmune disorders (such as IBD or systemic lupus erythematosus) consequently shaping the initiation and/or progression of the immune response [42](#embr201642412-bib-0042){ref-type="ref"}, [43](#embr201642412-bib-0043){ref-type="ref"}, [44](#embr201642412-bib-0044){ref-type="ref"}, [45](#embr201642412-bib-0045){ref-type="ref"}. Accordingly, CD1d expression is down‐regulated on IECs from patients with IBD and on B cells from patients with systemic lupus erythematosus, which correlates with abnormal function of IECs, B cells and NKT cells in these diseases. Thus, similarly to the protective role exerted by epithelial CD1d in intestinal inflammation by controlling IL‐10 secretion, CD1d on ILC3s may contribute to the regulation of immunity by modulating the production of IL‐22. Analyses of ILCs in human tissues will be crucial to define the expression of the different CD1 isoforms (CD1a‐d) in the ILC families and therefore identify their role in the regulation of iNKT cells in homeostasis and disease. Further studies will allow defining the mechanisms that control CD1d expression on ILC3s and the role of the ILC‐NKT cell axis in different diseases providing a novel target for immune intervention.

Materials and Methods {#embr201642412-sec-0006}
=====================

Reagents and mice {#embr201642412-sec-0007}
-----------------

C57BL/6 WT mice were purchased from Charles River and CD1d^−/−^ mice were bred at King\'s College London. All experiments were approved by the King\'s College London\'s Animal Welfare and Ethical Review Body and the United Kingdom Home Office (project licence 70/7907). iNKT hybridoma DN32.D3 was from A. Bendelac (University of Chicago). αGalCer was purchased from BioVision. PBS57‐loaded CD1d tetramers were provided by the NIH Tetramer Core Facility. BODIPY‐αGalCer was synthesized according to previously published protocols [46](#embr201642412-bib-0046){ref-type="ref"}.

Tissue preparation and flow cytometry {#embr201642412-sec-0008}
-------------------------------------

Tissues were processed as previously described [3](#embr201642412-bib-0003){ref-type="ref"} and single‐cell suspensions were used for flow cytometry. For SI‐LP lymphocyte preparations, intestines were isolated, PP removed, and intestines were flushed with cold PBS and cut open longitudinally. Tissues were incubated 20 min at 37°C in HBSS, 1 mM EDTA, 5% FCS to remove epithelial cells and intraepithelial lymphocytes. The lamina propria layer was isolated after incubation for 40 min at 37°C with collagenase (1.5 mg/ml) and DNase (100 μg/ml). Spleen and mLN were harvested and single‐cell suspensions obtained by mincing the tissue through a 45‐μm strainer.

Flow cytometry analyses were performed in FACS buffer containing PBS, 1% BSA and 1% FCS. Anti‐mouse CD16/32 (clone 2.4G2, Biolegend) was used to block non‐specific antibody binding. Afterwards cells were stained with the following antibodies, all from Biolegend unless specified otherwise: B220 (clone RA3‐6B2), CCR6 (clone 29‐2L17), CD117 (clone 2B8), CD11b (clone M1/70), CD11c (clone N418), CD127 (clone A7R34), CD1d (clone 1B1), CD3 (clone 145‐2C11), CD4 (clone GK1.5), CD45.2 (clone 104), CD5 (clone 53‐7.3), CD69 (clone H1.2F3), CD90 (clone 53‐2.1), I‐A/I‐E (clone M5‐114.15.2), NKp46 (clone 29A1.4), TCR‐β (clone H57‐587), sca‐1 (clone, D7), T‐bet (clone 4B10), PLZF (clone 9E12), GATA‐3 (clone TWAJ, eBioscience), RORγt (clone B2D, eBioscience).

For intracellular staining, cells were fixed and permeabilized with Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Dead cells were excluded from the analyses using a fixable viability stain (Biolegend). Flow cytometry data were collected on a FACSCanto II flow cytometer (BD Biosciences) and were analysed with FlowJo software (Tree Star).

Isolation, culture and stimulation of ILC3s {#embr201642412-sec-0009}
-------------------------------------------

For purification of ILC3s, single‐cell suspensions from mLNs and spleens were prepared by mincing the tissue through a 45‐μm strainer. Splenic ILC3s were enriched by using lineage cell depletion kit (Miltenyi Biotec). ILC3s were further purified by cell sorting as CD45^+^CD127^+^CD117^+^B220^−^CD3^−^CD5^−^CD11c^−^CD11b^−^ cells [3](#embr201642412-bib-0003){ref-type="ref"}, [9](#embr201642412-bib-0009){ref-type="ref"}, [28](#embr201642412-bib-0028){ref-type="ref"} with a FACSAria II (BD Biosciences). Sorted ILC3s were cultured in complete RPMI medium supplemented with 10% FCS. For cross‐linking experiments, ILCs were expanded for 5--8 days with IL‐7 (50 ng/ml) and IL‐2 (100 ng/ml) as described [28](#embr201642412-bib-0028){ref-type="ref"}, [47](#embr201642412-bib-0047){ref-type="ref"}.

Surface CD1d was cross‐linked by incubation of ILC3s with anti‐CD1d antibody (clone 1B1) followed by goat anti‐rat IgG as described [14](#embr201642412-bib-0014){ref-type="ref"}, [21](#embr201642412-bib-0021){ref-type="ref"}. In some experiments, cells were incubated with recombinant IL‐23 (100 ng/ml, Biolegend) or IL‐1β (100 ng/ml, Biolegend) and/or anti‐CD1d. For intracellular cytokine staining after cross‐linking, ILC3s were incubated with brefeldin A (5 μg/ml, Biolegend) for the final 2 h of stimulation, fixed and permeabilized with Fix/Perm buffer set (Biolegend) and stained for cytokine production with anti‐mouse IL‐22 (1H8PWSR, eBioscience). Dead cells were excluded from the analyses using a fixable viability stain (Biolegend). IL‐22 was measured in the cultures\' supernatant using IL‐22 ELISA MAX Deluxe (Biolegend).

For analysis of BODIPY‐αGalCer acquisition, ILC3s were incubated with fluorescent lipids (100 ng/ml) for 4--6 h before flow cytometry analyses. For analysis of fluorescent lipid uptake *in vivo*, mice were intravenously injected with BODIPY‐αGalCer (1 μg/mouse) in 200 μl of PBS. Lipid uptake was analysed by flow cytometry in the spleen 16 h after injection.

For αGalCer presentation analysis, sorted cells were incubated for 2 h with αGalCer (100 ng/ml), washed extensively and cultured (5 × 10^3^ cells/well) with 2 × 10^4^ cells/well of DN32.D3 cells for 16 h. IL‐2 concentration was determined by a standard sandwich ELISA in the supernatant of the culture medium, using anti‐IL‐2 (JES6‐1A12) antibody for capture and biotinylated anti‐IL‐2 (JES6‐5H4) antibody for detection (both from Biolegend).

ILC3 adoptive transfer and iNKT cell activation {#embr201642412-sec-0010}
-----------------------------------------------

ILC3s were incubated for 2 h with αGalCer (100 ng/ml) or PBS, washed extensively and adoptively transferred into WT recipients (0.5--1 × 10^5^ cells/mouse). Recipient mice were euthanized 18--24 h following transfer and iNKT cell activation was measured by qPCR and flow cytometry.

For qPCR analyses, iNKT cells were sort‐purified from the spleen, mLN and SI‐LP of recipient mice as TCR‐β^+^CD1d‐tetramer^+^B220^−^ cells and RNA was extracted as described below.

For intracellular IFN‐γ and IL‐4 staining, single‐cell suspension were prepared and stained with B220, TCR‐β and CD1d‐tetramer prior to fixation and permeabilization with Fix/Perm buffer set (Biolegend). Fixed cells were stained with anti‐mouse IFN‐γ (XMG1.2, Biolegend) and anti‐IL‐4 (11B11, Biolegend). Dead cells were excluded from the analyses using a fixable viability stain (Biolegend).

Quantitative real‐time PCR {#embr201642412-sec-0011}
--------------------------

RNA samples were prepared using RNeasy Mini Kit (Qiagen) and cDNAs were synthesized with iScript Select cDNA Synthesis Kit (Bio‐Rad). For gene expression analyses, we used SYBR green Master kit (Bio‐Rad) and the following primers: *GAPDH‐F*: 5′‐ACGACCCCTTCATTGAC‐3′; *GAPDH‐R*: 5′‐TCCACGACATACTCAGCAC‐3′; *LTA‐F*: 5′‐GCCATTCCCACTCCCATCTACCTG‐3′; *LTA‐R*: 5′‐CGCACCCACGGTCCTTGAAGTC‐3′; *LTB‐F*: 5′‐ACCTCATAGGCGCTTGGATG‐3′; *LTB‐R*: 5′‐ACGCTTCTTCTTGGCTCGC‐3′; *IL17A‐F*: 5′‐AGCAAGAGATCCTGGTCCTGAA‐3′; *IL17A‐R*: 5′‐CATCTTCTCGACCCTGAAAGTGA‐3′; *IL22‐F*: 5′‐GACCAAACTCAGCAATCAGCTC‐3′; *IL22‐R*: 5′‐TACAGACGCAAGCATTTCTCAG‐3′; *CD40L‐F*: 5′‐AGCTGGTGCTTCTGTGTTTGTC‐3′; *CD40L‐R:* 5′‐AAGATGAGAAGCCAACTCTGTGG‐3′; *TNFSF13‐F*: 5′‐ACCCAGAAGCACAAGAAGAAGC‐3′; *TNFSF13‐R*: 5′‐GTACTGGTTGCCACATCACCTC‐3′; *TNFSF13B‐F*: 5′‐AGCTGAGCCTGGTGACCCTGTTC‐3′; *TNFSF13B‐R*: 5′‐TCTCATCTCCTTCTTCCAGCCTCGC‐3′; *IL4‐F*: 5′‐AAGAACACCACAGAGAGTGAGCTC‐3′; *IL4‐R*: 5′‐TTTCAGTGATGTGGACTTGGACTC‐3′; *IL10‐F*: 5′‐AGAAGCATGGCCCTGAAATCAAGG‐3′; *IL‐10‐R*: 5′‐CTTGTAGACACCTTGGTCTTGGAG‐3′; *IFNG‐F*: 5′‐GCCATCAGCAACAACATAAGCGTC‐3′; *IFNG‐R*: 5′‐CCACTCGGATGAGCTCATTGAATG‐3′; *CD1D‐F*: 5′‐GAATGACACCTGCCCCCTATT‐3′; *CD1D‐R:* 5′‐ACCCACACAGGTTTTGGGTA‐3′. Reactions were run in a real‐time PCR system (ABI7900HT; Applied Biosystems).
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